title: Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.
abstract: We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2-50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889-39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.
authors.affiliation: Hospital Mútua de Terrassa, University of Barcelona, Spain. carolgv75@hotmail.com
authors.forename: C
authors.initials: C
authors.lastname: Garcia-Vidal
authors.forename: S
authors.initials: S
authors.lastname: Rodríguez-Fernández
authors.forename: S
authors.initials: S
authors.lastname: Teijón
authors.forename: M
authors.initials: M
authors.lastname: Esteve
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez-Carballeira
authors.forename: J M
authors.initials: JM
authors.lastname: Lacasa
authors.forename: G
authors.initials: G
authors.lastname: Salvador
authors.forename: J
authors.initials: J
authors.lastname: Garau
mesh_terms: D000038:Abscess / Q000453:epidemiology / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D015331:Cohort Studies; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology / Q000209:etiology; D006563:Herpes Zoster Ophthalmicus / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007107:Immune System / Q000187:drug effects; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000069285:Infliximab; D007898:Leishmaniasis, Visceral / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D018709:Statistics, Nonparametric; D014376:Tuberculosis / Q000453:epidemiology / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab
references.citation: Ann Rheum Dis. 2007 Dec;66(12):1610-5
references.pmid: 17456528
references.citation: Lancet. 2003 Nov 29;362(9398):1828-38
references.pmid: 14654323
references.citation: Vaccine. 2008 Jun 25;26(27-28):3528-33
references.pmid: 18502006
references.citation: Ann Rheum Dis. 2006 Feb;65(2):191-4
references.pmid: 16014674
references.citation: Arthritis Rheum. 2006 Aug;54(8):2368-76
references.pmid: 16868999
references.citation: Clin Infect Dis. 2005 Mar 1;40(5):756-9
references.pmid: 15714425
references.citation: Clin Infect Dis. 2007 Oct 1;45(7):826-36
references.pmid: 17806046
references.citation: Arthritis Rheum. 2004 Jun;50(6):1959-66
references.pmid: 15188373
references.citation: Arthritis Rheum. 2002 Sep;46(9):2294-300
references.pmid: 12355476
references.citation: Immunol Today. 1992 Apr;13(4):136-42
references.pmid: 1374612
references.citation: Arthritis Rheum. 2005 Jun;52(6):1766-72
references.pmid: 15934089
references.citation: N Engl J Med. 2001 Oct 11;345(15):1098-104
references.pmid: 11596589
references.citation: Gut. 2004 Sep;53(9):1363-5
references.pmid: 15306601
references.citation: Lancet Infect Dis. 2003 Mar;3(3):148-55
references.pmid: 12614731
references.citation: N Engl J Med. 1988 Jun 2;318(22):1423-31
references.pmid: 3259286
references.citation: J Rheumatol. 2007 May;34(5):952-7
references.pmid: 17444589
references.citation: Clin Infect Dis. 2007 Oct 1;45(7):837-45
references.pmid: 17806047
references.citation: Crit Care Clin. 2002 Oct;18(4):931-56
references.pmid: 12418448
references.citation: Medicine (Baltimore). 2005 Sep;84(5):291-302
references.pmid: 16148729
references.citation: Best Pract Res Clin Rheumatol. 2003 Apr;17(2):345-63
references.pmid: 12787529
references.citation: Arthritis Rheum. 2006 Feb 15;55(1):19-26
references.pmid: 16463407
references.citation: Clin Infect Dis. 2004 May 1;38(9):1261-5
references.pmid: 15127338
references.citation: Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13
references.pmid: 15067625
references.citation: Semin Arthritis Rheum. 2004 Feb;33(4):283-8
references.pmid: 14978666
references.citation: Clin Infect Dis. 2006 Nov 15;43(10):e95-100
references.pmid: 17051484
references.citation: Inflamm Bowel Dis. 2007 Nov;13(11):1450-1
references.pmid: 17712837
references.citation: Rheumatol Int. 1990;10(4):165-9
references.pmid: 2259842